The economic case for typhoid conjugate vaccines in countries with medium and high incidence of infection

Lancet Infect Dis. 2019 Jul;19(7):675-676. doi: 10.1016/S1473-3099(19)30054-4. Epub 2019 May 23.

Authors

Youngji Jo¹, David W Dowdy²

Affiliations

¹ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
² Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA. Electronic address: [email protected].

PMID: 31130328
DOI: 10.1016/S1473-3099(19)30054-4

No abstract available

Publication types

Comment

MeSH terms

Cost-Benefit Analysis
Humans
Incidence
Salmonella typhi
Typhoid Fever*
Typhoid-Paratyphoid Vaccines*
Vaccines, Conjugate

Substances

Typhoid-Paratyphoid Vaccines
Vaccines, Conjugate